ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 51 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,069,574 | +1197.9% | 115,008 | +1283.0% | 0.00% | – |
| Q1 2024 | $82,411 | +198.7% | 8,316 | -2.6% | 0.00% | – |
| Q4 2023 | $27,590 | -88.1% | 8,542 | -80.5% | 0.00% | – |
| Q3 2023 | $232,383 | -32.6% | 43,763 | +20.9% | 0.00% | – |
| Q2 2023 | $344,964 | +84.1% | 36,184 | +112.4% | 0.00% | – |
| Q1 2023 | $187,396 | -20.5% | 17,036 | +6.9% | 0.00% | – |
| Q4 2022 | $235,852 | -19.0% | 15,936 | +4.8% | 0.00% | – |
| Q3 2022 | $291,000 | +15.5% | 15,213 | +28.9% | 0.00% | – |
| Q2 2022 | $252,000 | +50.0% | 11,804 | +35.2% | 0.00% | – |
| Q1 2022 | $168,000 | -7.2% | 8,732 | 0.0% | 0.00% | – |
| Q4 2021 | $181,000 | -13.4% | 8,732 | 0.0% | 0.00% | – |
| Q3 2021 | $209,000 | +102.9% | 8,732 | +130.8% | 0.00% | – |
| Q2 2021 | $103,000 | -17.6% | 3,783 | -12.7% | 0.00% | – |
| Q1 2021 | $125,000 | +83.8% | 4,333 | +79.5% | 0.00% | – |
| Q4 2020 | $68,000 | +7.9% | 2,414 | +11.9% | 0.00% | – |
| Q3 2020 | $63,000 | +31.2% | 2,157 | +37.3% | 0.00% | – |
| Q2 2020 | $48,000 | 0.0% | 1,571 | -2.8% | 0.00% | – |
| Q1 2020 | $48,000 | – | 1,617 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $128,526,634 | 7.99% |
| Saturn V Capital Management LP | 487,179 | $8,787,113 | 7.29% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $44,400 | 4.96% |
| Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $8,421,807 | 3.66% |
| Logos Global Management LP | 1,400,000 | $20,720,000 | 2.43% |
| Rubric Capital Management LP | 2,742,519 | $40,589,281 | 1.77% |
| 1492 Capital Management LLC | 174,546 | $2,583,281 | 1.67% |
| AlphaCentric Advisors LLC | 78,500 | $1,161,800 | 1.15% |
| MPM BioImpact LLC | 262,069 | $3,878,621 | 1.01% |
| Orbimed Advisors | 2,460,108 | $36,409,598 | 0.70% |